Semaglutide was developed based on GLP-1(7-37) backbone, its Lys side chain was modified with a long chain fatty acid, enabling it to bind to plasma albumin for slower drug release
This Journal Club focuses on the SELECT Trial Table of contents for the The SELECT Trial summary: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes A
When to seek immediate medical attention: Severe abdominal pain that doesn't resolve, possibly radiating to the back (potential pancreatitis) Persistent nausea and vomiting preventing adequate fluid intake (dehydration risk) Signs of allergic reaction: difficulty breathing, swelling of face or throat, severe rash Symptoms of thyroid tumors: lump in neck, hoarseness, difficulty swallowing (rare but serious) Severe hypoglycemia symptoms when used with insulin or sulfonylureas: confusion, seizures, loss of consciousness Changes in vision or eye pain (potential diabetic retinopathy complications, particularly with rapid improvement in blood glucose) Signs of kidney problems: decreased urination, swelling in legs or feet, unusual fatigue Symptoms of gallbladder problems: pain in right or middle upper abdomen, fever, yellowing of skin/eyes These medications carry a boxed warning regarding the risk of thyroid C-cell tumors, based on animal studies
Dont mention GLP-1s: Although 59% of diners would be likely to order smaller, protein-based menu items, over 37% say they are absolutely not interested in a menu labeled as GLP-1 meaning there is interest in the offering but not the identity 7
